Contact | Print version | PDF version | Send article | RSS feed

ImmunoVaccine Technologies Inc. to Acquire Immunotope Inc.

12 Dec 2007 - ImmunoVaccine Technologies Inc. (IVT) has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of cancer and infectious diseases.
 
The acquisition will bring together IVT's signature VacciMax(R) platform with Immunotope's portfolio of immunotherapeutic antigens and antigen discovery platform, allowing the new private company to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines.
 
The combined clinical-stage company will continue to support Immunotope's ongoing Phase 1 immunotherapeutic vaccine clinical trial in ovarian and breast cancer patients at Duke University Comprehensive Cancer Center.